AdagrasibA Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies

Sponsor:

Mirati Therapeutics Inc.

Code:

NCT07415031

Conditions

Solid Tumors

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Adagrasib

Pembrolizumab

Cetuximab

Pemetrexed

Docetaxel

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-08-25. This information was provided to ClinicalTrials.gov by Mirati Therapeutics Inc. on 2026-08-18.